Navigation Links
HIV drug resistance risk in mothers reduced by combination of common drugs
Date:11/9/2007

BIRMINGHAM, Ala. -- New research from the University of Alabama at Birmingham (UAB) shows that adding a single dose of two common anti-HIV drugs can prevent HIV-positive pregnant women from developing resistance to an entire class of drugs, potentially improving future treatment options.

Providing tenofovir and emtricitabine with nevirapine during labor greatly reduces the extent of resistance to non-nucleoside reverse transcriptate inhibitors (NNRTIs), such as nevirapine, which HIV-positive women take to lower the risk of mother-to-child transmission during childbirth.

Benjamin Chi, M.D., assistant professor of obstetrics and gynecology at UAB, and colleagues, reported their findings online in this weeks edition of The Lancet. Chi said the drug combination reduced resistance to NNRTIs by more than half at six weeks after delivery. This finding is important because between 20 and 69 percent of women given nevirapine develop resistance to the NNRTIs after taking a single dose. Although resistance becomes undetectable one to two years after ingestion, there are concerns that it could still compromise a womans future treatment options.

In this study, 399 participants were randomly assigned to receive or not receive single dose tenofovir and emtricitabine along with routine care. Routine care meant starting the anti-HIV drug zidovudine (or AZT) at 32 weeks gestation, and then ingesting a single dose of nevirapine at the start of labor. Participants were healthy and did not yet require treatment with potent antiretroviral therapy. The main goal of the study was to see if there was a difference in the presence of NNRTI resistance mutations six weeks after giving birth. The study was conducted in Lusaka, Zambia between 2005 and 2007.

Overall, 12 percent of women given the tenofovir and emtricitabine dose developed NNRTI resistance, compared to 25 percent among those who did not receive the additional drugs. Tenofovir and emtricitabine appeared to be safe, with no attributable side effects. Although these additional drugs did prevent NNRTI resistance, their use did not lead to substantial reductions in mother-to-child HIV transmission.

These results are encouraging for places like Zambia, which must rely on nevirapine for both HIV prevention and treatment. The simplicity and effectiveness of this regimen is an important aspect of this intervention, Chi said.

HIV-infected pregnant women who take nevirapine in labor now have an easy way to reduce some of the negative consequences associated with the drug.


'/>"/>

Contact: Jennifer Lollar
jpark@uab.edu
205-934-3888
University of Alabama at Birmingham
Source:Eurekalert

Related medicine news :

1. Fat on chest and upper back increases risk of insulin resistance
2. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
3. Cell skeleton may hold key to overcoming drug resistance in cancer
4. Genetic approach provides new insight into trastuzumab resistance in breast cancer
5. Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies
6. FDA Warns of Codeine Risk for Some Nursing Mothers
7. Mothers Know Best: NFL Moms Team With Eddie George to Showcase a Better Way to a Healthier Lifestyle
8. Hip size of mothers linked to breast cancer in daughters
9. Overweight mothers run greater risk of having hyperactive children
10. New Case Study Details How an Illinois Hospital Created a Safe Lifting Team that Dramatically Reduced Injuries, Increased Staff Satisfaction
11. Giving emergency nurses aromatherapy massages with music dramatically reduced stress levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2017)... ... January 22, 2017 , ... "Photo Cloud allows FCPX users to ... 3D slideshow with complete ease," said Christina Austin - CEO of Pixel Film Studios. ... the FCPX timeline. Presets include scenes with one, three, four or five ...
(Date:1/21/2017)... ... January 21, 2017 , ... Caronlab Australia, an Australian ... January ECRM Trade Show in Hilton Head, SC, where it benefited from outstanding meetings ... quality of its beauty and wellness products. At this trade show, the company had ...
(Date:1/21/2017)... ... ... "ProDOF is the perfect set of tools for video editors that want to create the ... Austin - CEO of Pixel Film Studios. , Video editors using ProDOF can add ... DSLR racking focus from one area into the next. ProDOF comes with 0.5 second, ...
(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites you to take an ... of the world with ZANZIBAR SHOWER GEL. Inspired by the beauty of Zanzibar, a ... Oil and moisturizing vegetal coral to create this gentle, crystal-clear shower gel to cleanse ...
(Date:1/21/2017)... ... January 21, 2017 , ... Northern California Medical Associates ... joined their multi-specialty medical group. The dermatology practice provides general dermatologic treatment, outpatient ... to add this excellent dermatology practice to our group’s medical services,” explains NCMA ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 This report ... current and future scenario of the global market. Large ... opioid consumption. Severe chronic constipation is a major side ... traditional laxatives. Hence, novel targeted therapy has been prescribed ... sufferers, launch of targeted medicines, and growing awareness about ...
(Date:1/19/2017)... Accuray Incorporated (Nasdaq: ARAY ) ... to set the bar for excellence in customer satisfaction. ... satisfaction rating among radiation treatment delivery systems in the ... Intelligence Briefing™. The most recent ratings trend also shows ... peers for 11 of the past 12 quarters. ...
(Date:1/19/2017)... January 19, 2017 Shire plc ... the U.S. Food and Drug Administration (FDA) has acknowledged ... Drug Application (NDA) for SHP465, a long-acting, triple-bead, mixed ... potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA ... June 20, 2017, the designated Prescription Drug User Fee ...
Breaking Medicine Technology: